Related Experiment Videos
[Thyroid dysfunction in patients with chronic hepatitis C pre and post treatment with interferon]
R Martín-Vivaldi1, F Nogueras, D Quintero
1Servicio de Digestivo, Hospital Virgen de las Nieves Granada.
Revista Espanola De Enfermedades Digestivas
|July 1, 1996
Summary
Interferon therapy for chronic hepatitis C can lead to thyroid dysfunction, particularly hypothyroidism, in 6% of patients. Pre-existing thyroid issues and specific patient factors influence this risk.
Area of Science:
- Endocrinology
- Hepatology
- Immunology
Context:
- Chronic hepatitis C is a significant global health concern.
- Interferon therapy has been a primary treatment for chronic hepatitis C.
- Thyroid function can be affected by systemic inflammatory and autoimmune processes.
Purpose:
- To investigate the incidence and characteristics of thyroid dysfunction following interferon therapy in chronic hepatitis C patients.
- To identify risk factors associated with interferon-induced thyroid dysfunction.
- To evaluate the role of pre-existing thyroid autoimmunity.
Summary:
- Interferon therapy, including interferon alfa and beta, was administered to 119 chronic hepatitis C patients.
- Thyroid function tests (free thyroxine, TSH, antibodies) were monitored before, during, and after treatment in a subset of patients.
- Biochemical thyroid dysfunction, predominantly hypothyroidism, occurred in 6% of treated patients, with higher rates in females, older individuals, and those receiving higher interferon doses. Antithyroid antibodies increased in some cases.
Impact:
- Interferon therapy can precipitate autoimmune thyroid phenomena.
- Pre-treatment screening for antithyroid antibodies and thyroid function is crucial.
- Identifying risk factors like age, sex, and interferon dose aids in patient management and risk stratification.